ASX ANNOUNCEMENT 30 October 2026 Results of Fully Underwritten Entitlement Offer Melbourne, Australia; 30 October 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), advises the results of its fully underwritten pro-rata renounceable entitlement offer...
Results of Fully Underwritten Entitlement Offer
Filed with ASX · · 1 page · English
Summary by 6ix AI
Cynata Therapeutics Limited reports the results of its fully underwritten entitlement offer, which closed recently. The company received valid applications for a portion of the new shares and entitlement options, indicating a modest take-up rate. The remaining shares will be subscribed for by the underwriter, Caravel Securities Pty Ltd, as per the underwriting agreement. Following the offer, the company expects to raise a total amount before costs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- September 2026 Quarterly Activity Report & Appendix 4C
- Letter to Shareholders, Notice of AGM & Proxy Form
- Paul Wotton to Resign as Director from AGM
- Unmarketable Parcel Sale Facility
- Notification of buy-back - CYP
Later from Cynata Therapeutics
- Consultancy Agreement
- Application for quotation of securities - CYP
- Cleansing Notice
- Notification regarding unquoted securities - CYP
- Appendix 3Y-Dr Geoffrey Brooke
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics